United Therapeutics Corporation Aktie News

United Therapeutics Corporation - Special Call Company Participants Harrison Silvers - Manager of Investor Relations Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation Martine Rothblatt - Founder, Chairman & CEO Conference Call Participants Steven D. Nathan Olivia Brayer - Cantor Fitzgerald & Co., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., ...

United Therapeutics Corporation (NASDAQ:UTHR ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:10 PM EDT Company Participants Harrison Silvers Martine Rothblatt - Founder, Chairman & CEO James Edgemond - CFO & Treasurer Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. East...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2nd Annual Healthcare Forum in New York. The session will take p...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands on September 27 - October 1, 2025. “On the heels of the remarkable topl...

United Therapeutics Corporation (NASDAQ:UTHR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants James Edgemond - CFO & Treasurer Harrison Silvers Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst All right. Great. Thanks.

United Therapeutics delivered strong phase 3 TETON-2 results for nebulized Tyvaso in IPF, meeting the primary endpoint and unlocking major catalyst potential. Tyvaso's efficacy in improving FVC in IPF could give it a competitive edge over current treatments and position UTHR to dominate a $5.46B market. Multiple upcoming catalysts include TETON-1 results (1H 2026), FDA meetings for label expans...

United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF). The trial met its primary endpoint, and the treatment showed good tolerability with a safety profile consistent with prior Tyvaso studies.